{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:07:32Z","timestamp":1789931252057,"version":"4.0.1"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["16\/44\/02"],"award-info":[{"award-number":["16\/44\/02"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2025,11,29]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although transcranial magnetic stimulation (TMS) protocols are safe and efficacious therapies for treatment-resistant depression (TRD), they remain inaccessible for many people in the UK and internationally. One of the main reasons for this is a lack of evidence demonstrating their value-for-money to commissioners.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the cost-effectiveness of repetitive transcranial magnetic stimulation therapy (rTMS) and intermittent theta-burst stimulation (iTBS) versus treatment-as-usual (TAU) for treating TRD in UK mental health care services, and to evaluate operational circumstances underpinning cost-effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This economic evaluation used data from the BRIGHTMIND trial (n=255), the SMD trial (n=187) and a study-specific structured expert elicitation exercise (n=7) to model the cost and consequences for each alternative. All findings were produced on a probabilistic basis from a Markov model using Monte Carlo simulation methods. Cost-effectiveness was assessed via incremental cost-effectiveness ratios (ICERs) per quality-adjusted life-year (QALY) gained over an 18-month time horizon from the perspectives of the UK\u2019s NHS and personal social services and from a broader societal perspective recognisant of informal care hours and productivity costs. Scenario analyses and an operational sensitivity analysis explored the impacts alternative methodologies, service delivery cases and perspectives had on base case findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>From a health service perspective, rTMS and iTBS had pairwise ICERs of \u00a312\u2009093 and \u00a312\u2009959 per QALY compared to TAU, respectively. When incrementally compared, iTBS had an ICER of \u00a316\u2009621 versus rTMS. From a broader societal perspective, both rTMS and iTBS reduced informal care hours and were cost-saving compared with TAU. Study findings were particularly sensitive to service delivery, with the probability of being cost-effective ranging from 98% with high throughput and prompt delivery to approximately 4% with low throughput and prolonged delivery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TMS therapies improve health, reduce informal care requirements, reduce health service utilisation and offset their costs when considered in terms of productivity losses to society. rTMS and iTBS are cost-effective and should be considered for wider clinical implementation provided they are delivered at sufficient scale and in a time-efficient manner.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>TMS can serve as a cost-effective alternative for treating moderate to severe depression after second-line treatment failure with non-psychological therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2025-302237","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:34:23Z","timestamp":1769628863000},"page":"e302237","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Is it time for mental health services to invest in neurostimulation? An economic evaluation of transcranial magnetic stimulation therapies for the treatment of moderate to severe treatment-resistant depression in the UK"],"prefix":"10.1136","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8981-0699","authenticated-orcid":false,"given":"Edward","family":"Cox","sequence":"first","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham School of Medicine, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ma","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham School of Medicine, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6279-6823","authenticated-orcid":false,"given":"Cristina","family":"Roadevin","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham School of Medicine, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Morriss","sequence":"additional","affiliation":[{"name":"Academic Unit of Mental Health and Neuroscience, University of Nottingham School of Medicine, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"James","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham School of Medicine, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"2026091806101573000_29.1.e302237.1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(24)00222-0"},{"key":"2026091806101573000_29.1.e302237.2","unstructured":"Mental health brain health and substance use (MSD). Depression and other common mental disorders global health estimates. Geneva World Health Organization; 2017.24. Available: https:\/\/www.who.int\/publications\/i\/item\/depression-global-health-estimates [accessed 12 Feb 2025]"},{"key":"2026091806101573000_29.1.e302237.3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/09638237.2017.1417562","article-title":"The economic cost of treatment-resistant depression in patients referred to a specialist service","volume":"27","author":"McCrone","year":"2018","journal-title":"J Ment Health"},{"key":"2026091806101573000_29.1.e302237.4","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jad.2021.12.090","article-title":"Health-related quality of life burden associated with treatment-resistant depression in UK patients: Quantitative results from a mixed-methods non-interventional study","volume":"300","author":"Rathod","year":"2022","journal-title":"J Affect Disord"},{"key":"2026091806101573000_29.1.e302237.5","unstructured":"Royal College of Psychiatrists . Statement on repetitive transcranial magnetic stimulation for depression. 2017. Available: https:\/\/www.rcpsych.ac.uk\/docs\/default-source\/about-us\/who-we-are\/ect-committee\/ectcommittee-repetative-transcranial-magnetic-stimulation-statement-may18.pdf?sfvrsn=695e93be_6#:~:text=Over%20the%20last%20decade%20rTMS,the%20updated%20guidance%20from%20NICE [Accessed 20 Jun 2025]."},{"key":"2026091806101573000_29.1.e302237.6","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13r08815"},{"key":"2026091806101573000_29.1.e302237.7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/00048674241249846","article-title":"Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the administration of repetitive transcranial magnetic stimulation","volume":"58","author":"Hussain","year":"2024","journal-title":"Aust N Z J Psychiatry"},{"key":"2026091806101573000_29.1.e302237.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02764-z"},{"key":"2026091806101573000_29.1.e302237.9","unstructured":"National Institute for Health and Care Excellence . Interventional procedures programme [IPG542]: repetitive transcranial magnetic stimulation for depression. 2015."},{"key":"2026091806101573000_29.1.e302237.10","doi-asserted-by":"publisher","DOI":"10.1177\/07067437241245384"},{"key":"2026091806101573000_29.1.e302237.11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/YCO.0000000000001029","article-title":"Scaling up a success story: how do we achieve universal access to transcranial magnetic stimulation?","volume":"38","author":"Downar","year":"2025","journal-title":"Curr Opin Psychiatry"},{"key":"2026091806101573000_29.1.e302237.12","unstructured":"Health Technology Wales . Transcranial magnetic stimulation. Available: https:\/\/healthtechnology.wales\/reports-guidance\/transcranial-magnetic-stimulation\/ [Accessed 27 Feb 2025]."},{"key":"2026091806101573000_29.1.e302237.13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S2215-0366(16)30143-2","article-title":"Efficacy and cost-effectiveness of a specialist depression service versus usual specialist mental health care to manage persistent depression: a randomised controlled trial","volume":"3","author":"Morriss","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"2026091806101573000_29.1.e302237.14","unstructured":"Depression in adults: treatment and management NICE guideline. 2022. Available: www.nice.org.uk\/guidance\/ng222 [Accessed 06 Nov 2025]."},{"key":"2026091806101573000_29.1.e302237.15","doi-asserted-by":"publisher","DOI":"10.3310\/hta25590"},{"key":"2026091806101573000_29.1.e302237.16","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1056210","article-title":"Economic evaluation of interventions for treatment-resistant depression: A systematic review","volume":"14","author":"Hannah","year":"2023","journal-title":"Front Psychiatry"},{"key":"2026091806101573000_29.1.e302237.17","doi-asserted-by":"publisher","DOI":"10.1136\/eb-2015-102299"},{"key":"2026091806101573000_29.1.e302237.18","unstructured":"NICE health technology evaluations: the manual nice process and methods. 2022. Available: www.nice.org.uk\/process\/pmg36 [Accessed 29 Jul 2025]."},{"key":"2026091806101573000_29.1.e302237.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.12.067"},{"key":"2026091806101573000_29.1.e302237.20","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-013-0104-z"},{"key":"2026091806101573000_29.1.e302237.21","doi-asserted-by":"crossref","first-page":"115573","DOI":"10.1016\/j.psychres.2023.115573","article-title":"Cost-effectiveness analysis comparing repetitive transcranial magnetic stimulation therapy with antidepressant treatment in patients with treatment-resistant depression in Japan","volume":"330","author":"Noda","year":"2023","journal-title":"Psychiatry Res"},{"key":"2026091806101573000_29.1.e302237.22","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jad.2024.04.075","article-title":"Cost-utility analysis of adjunct repetitive transcranial magnetic stimulation for treatment resistant bipolar depression","volume":"356","author":"Chatterton","year":"2024","journal-title":"J Affect Disord"},{"key":"2026091806101573000_29.1.e302237.23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/acps.13782","article-title":"Cost-Effectiveness of rTMS as a Next Step in Antidepressant Non-Responders: A Randomized Comparison With Current Antidepressant Treatment Approaches","volume":"151","author":"Dalhuisen","year":"2025","journal-title":"Acta Psychiatr Scand"},{"key":"2026091806101573000_29.1.e302237.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222546","article-title":"Implementation of intermittent theta burst stimulation compared to conventional repetitive transcranial magnetic stimulation in patients with treatment resistant depression: A cost analysis","volume":"14","author":"Mendlowitz","year":"2019","journal-title":"PLoS ONE"},{"key":"2026091806101573000_29.1.e302237.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-022-04078-9","article-title":"Repetitive transcranial magnetic stimulation may be a cost-effective alternative to antidepressant therapy after two treatment failures in patients with major depressive disorder","volume":"22","author":"Zempl\u00e9nyi","year":"2022","journal-title":"BMC Psychiatry"},{"key":"2026091806101573000_29.1.e302237.26","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-009-0013-x"},{"key":"2026091806101573000_29.1.e302237.27","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jval.2015.04.004","article-title":"Cost-Effectiveness of Repetitive Transcranial Magnetic Stimulation versus Antidepressant Therapy for Treatment-Resistant Depression","volume":"18","author":"Nguyen","year":"2015","journal-title":"Value Health"},{"key":"2026091806101573000_29.1.e302237.28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1176\/appi.ajp.20240604","article-title":"Positioning rTMS Within a Sequential Treatment Algorithm of Depression","volume":"181","author":"Kaster","year":"2024","journal-title":"AJP"},{"key":"2026091806101573000_29.1.e302237.29","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/PPA.S105654","article-title":"Comparison between neurostimulation techniques repetitive transcranial magnetic stimulation vs electroconvulsive therapy for the treatment of resistant depression: patient preference and cost-effectiveness","volume":"10","author":"Magnezi","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2026091806101573000_29.1.e302237.30","first-page":"164","article-title":"Cost-Utility Analysis of Electroconvulsive Therapy and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression in Ontario","volume":"65","author":"Fitzgibbon","year":"2020","journal-title":"Can J Psychiatry"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2025-302237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:31:41Z","timestamp":1789929101000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2025-302237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,27]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjment-2025-302237"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2025-302237","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}